E-Scape Bio, a spinout of Gladstone Institutes, has achieved a final close of its series A thanks to commitments from Osage University Partners and several corporates.
E-Scape Bio, a US-based biopharmaceutical spinout of Gladstone Institutes targeting neurodegenerative diseases, closed a $63m series A round yesterday backed by spinout-focused investment firm Osage University Partners.
The round consisted of two tranches, with Osage participating in a first $55m close led by OrbiMed in 2015.
The first portion also included pharmaceutical firms Novo, Johnson and Johnson and Novartis – the latter two took part through respective investment units Johnson & Johnson Innovation – JJDC and Novartis Venture Fund.
Lilly…
